Elzonris
Elzonris ingredients
| Active ingredient | Strength |
|---|---|
| Tagraxofusp | 1000 ug/mL |
What Elzonris is used for
The FDA lists the approved uses on the official label (below). In the EU, tagraxofusp is approved as Elzonris for:
Elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Elzonris
- Generic name
- Tagraxofusp
- Made by
- Stemline Therapeutics, Inc.
- Forms
- Injection, Solution
- Given
- Intravenous
- Drug class
- CD123 Interaction, Cytotoxin
- FDA approval
- Biologic licence (BLA) BLA761116
- On the US market since
- 2019
Official information
- Elzonris prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Tagraxofusp)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Elzonris?
Elzonris (Tagraxofusp) is a cancer medicine made by Stemline Therapeutics, Inc., approved by the US FDA.
What are the ingredients of Elzonris?
Elzonris contains Tagraxofusp (1000 ug/mL).
Is Elzonris approved in Europe?
The same active substance is approved in the EU as Elzonris.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA